MedTrace Logo

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT06997029 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Conditions

Interventions

DRUG

BMS-986500

Specified dose of specified days

DRUG

Palbociclib

Specified dose on specified days

DRUG

Fulvestrant

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2028-12-14
Completion
2028-12-14
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06997029 on ClinicalTrials.gov